Moreover, to our knowledge, reduced plasmablast depletion efficacy was linked for the first time to sub-optimal response to anti-CD20 treatment in active progressive MS, and this effect may be independent of IL-6 regulation. This evidence concerns the gene IL6 and myeloid sarcoma.